A microarray-based system for the simultaneous analysis of single nucleotide polymorphisms in human genes involved in the metabolism of anti-malarial drugs

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Hodel, Eva Maria ^a   Ley, Serej D ^a,d   Qi, Weihong ^a,e   Ariey, Frédéric ^b   Genton, Blaise ^a,c   Beck, Hans Peter ^a  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^e FUNCTIONAL GENOMICS CENTER ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450; NAT2 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MICROARRAY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; CAMBODIA; COMPARATIVE STUDY; DNA MICROARRAY; DRUG EFFECT; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; PARASITOLOGY; PLASMODIUM; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TANZANIA;

ANTIMALARIALS; ARYLAMINE N-ACETYLTRANSFERASE; CAMBODIA; CYTOCHROME P-450 ENZYME SYSTEM; GENETIC VARIATION; GENOTYPE; HUMANS; MALARIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASMODIUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SENSITIVITY AND SPECIFICITY; TANZANIA;

EID: 73549097301     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-285     Document Type: Article

References (44)

1. The human genome project and novel aspects of cytochrome P450 research. M Ingelman-Sundberg, Toxicol Appl Pharmacol 2005 207 2 Suppl 52 56 10.1016/j.taap.2005.01.030 15993453
2. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. M Ingelman-Sundberg C Rodriguez-Antona, Philos Trans R Soc Lond B Biol Sci 2005 360 1460 1563 1570 10.1098/rstb.2005.1685 16096104
3. SNPs in forensic genetics: a review on SNP typing methodologies. B Sobrino M Brián A Carracedo, Forensic Sci Int 2005 154 2-3 181 94 10.1016/j.forsciint.2004.10.020 16182964
4. SNP typing in forensic genetics: a review. B Sobrino A Carracedo, Methods Mol Biol 2005 297 107 26 15570103
5. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. A Crameri J Marfurt K Mugittu N Maire A Regös J Coppee O Sismeiro R Burki E Huber D Laubscher O Puijalon B Genton I Felger HP Beck, J Clin Microbiol 2007 45 11 3685 3691 10.1128/JCM.01178-07 17804664
6. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. J Miller L Trepanier, Eur J Clin Pharmacol 2002 58 1 69 72 10.1007/s00228-002-0424-y 11956677
7. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. X Li A Björkman T Andersson M Ridderström C Masimirembwa, J Pharmacol Exp Ther 2002 300 2 399 407 10.1124/jpet.300.2.399 11805197
8. The potential for interactions between antimalarial and antiretroviral drugs. S Khoo D Back P Winstanley, AIDS 2005 19 10 995 1005 10.1097/01.aids. 0000174445.40379.e0 15958830 (Pubitemid 40961139)
9. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. N White M van Vugt F Ezzet, Clin Pharmacokinet 1999 37 2 105 125 10.2165/00003088-199937020-00002 10496300
10. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. U Svensson M Ashton, Br J Clin Pharmacol 1999 48 4 528 535 10.1046/j.1365-2125.1999.00044.x 10583023
11. Pharmacokinetic interactions of antimalarial agents. P Giao P de Vries, Clin Pharmacokinet 2001 40 5 343 373 10.2165/00003088-200140050-00003 11432537
12. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. X Li A Björkman T Andersson L Gustafsson C Masimirembwa, Eur J Clin Pharmacol 2003 59 5-6 429 442 10.1007/s00228-003-0636-9 12920490
13. Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. J Grace A Aguilar K Trotman J Peggins T Brewer, Drug Metab Dispos 1998 26 4 313 317 9531517
14. In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. D Projean B Baune R Farinotti J Flinois P Beaune A Taburet J Ducharme, Drug Metab Dispos 2003 31 6 748 754 10.1124/dmd.31.6.748 12756207
15. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. K Kim J Park J Lee S Lim, Arch Pharm Res 2003 26 8 631 637 10.1007/BF02976712 12967198
16. An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. R Halliday B Jones D Smith N Kitteringham B Park, Br J Clin Pharmacol 1995 40 4 369 378 8554939
17. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. F Fontaine G de Sousa P Burcham P Duchne R Rahmani, Life Sci 2000 66 22 2193 2212 10.1016/S0024-3205(00)00546-4 10834303
18. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers. W Ridtitid M Wongnawa W Mahatthanatrakul N Raungsri M Sunbhanich, J Clin Pharm Ther 2005 30 3 285 290 10.1111/j.1365-2710.2005. 00651.x 15896247
19. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers. W Ridtitid M Wongnawa W Mahatthanatrakul P Chaipol M Sunbhanich, J Pharm Pharmacol 2000 52 10 1265 1269 10.1211/0022357001777243 11092571
20. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. A Kaneko Y Bergqvist G Taleo T Kobayakawa T Ishizaki A Björkman, Pharmacogenetics 1999 9 3 317 326 10471063
21. Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. E Skjelbo T Mutabingwa I Bygbjerg K Nielsen L Gram K Brøosen, Clin Pharmacol Ther 1996 59 3 304 311 10.1016/S0009-9236(96)80008-7 8653993
22. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. R Mirghani U Yasar T Zheng J Cook L Gustafsson G Tybring O Ericsson, Drug Metab Dispos 2002 30 12 1368 1371 10.1124/dmd.30.12.1368 12433805
23. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. R Mirghani U Hellgren P Westerberg O Ericsson L Bertilsson L Gustafsson, Clin Pharmacol Ther 1999 66 5 454 460 10.1016/S0009-9236(99)70008-1 10579472
24. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. H Zhang P Coville R Walker J Miners D Birkett S Wanwimolruk, Br J Clin Pharmacol 1997 43 3 245 252 10.1046/j.1365-2125.1997.00556.x 9088578
25. Isoniazid acetylating phenotype in patients with paracoccidioidomycosis and its relationship with serum sulfadoxin levels, glucose-6-phosphate dehydrogenase and glutathione reductase activities. B Barraviera P Pereira J Machado M de Souza C Lima P Curi R Mendes D Meira, Rev Soc Bras Med Trop 24 2 111 114 1841426
26. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. A Alfirevic A Stalford F Vilar E Wilkins B Park M Pirmohamed, Br J Clin Pharmacol 2003 55 2 158 165 10.1046/j.1365-2125. 2003.01754.x 12580987
27. Pharmacogenetics of the cytochromes P450. A Daly, Curr Top Med Chem 2004 4 16 1733 1744 10.2174/1568026043387070 15579105
28. Amodiaquine pharmacogenetics. J Gil, Pharmacogenomics 2008 9 10 1385 1390 10.2217/14622416.9.10.1385 18855526
29. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. R Mehlotra C Henry-Halldin P Zimmerman, Pharmacogenomics 2009 10 3 435 449 10.2217/14622416.10.3.435 19290792
30. Characterization of human urinary metabolites of the antimalarial piperaquine. J Tarning Y Bergqvist N Day J Bergquist B Arvidsson N White M Ashton N Lindegårdh, Drug Metab Dispos 2006 34 12 2011 2019 10.1124/dmd.106.011494 16956956
31. Plasma pyrimethamine concentrations during long-term treatment for cerebral toxoplasmosis in patients with AIDS. H Klinker P Langmann E Richter, Antimicrob Agents Chemother 1996 40 7 1623 1627 8807051
32. Lipid-soluble inhibitors of dihydrofolate reductase. I. Kinetics, tissue distribution, and extent of metabolism of pyrimethamine, metoprine, and etoprine in the rat, dog, and man. J Cavallito C Nichol WJ Brenckman R Deangelis D Stickney W Simmons C Sigel, Drug Metab Dispos 6 3 329 337 26555
33. In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization. J Lee J Son S Chung E Lee D Kim, J Mass Spectrom 2004 39 9 1036 1043 10.1002/jms.663 15386754
34. Disposition of atovaquone in humans. P Rolan A Mercer E Tate I Benjamin J Posner, Antimicrob Agents Chemother 1997 41 6 1319 1321 9174191
35. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. K Agwuh A MacGowan, J Antimicrob Chemother 2006 58 2 256 265 10.1093/jac/dkl224 16816396
36. ROC with confidence - a Perl program for receiver operator characteristic curves. H Kestler, Comput Methods Programs Biomed 2001 64 2 133 136 10.1016/S0169-2607(00)00098-5 11137196
37. The measurement of observer agreement for categorical data. J Landis G Koch, Biometrics 1977 33 1 159 174 10.2307/2529310 843571
38. Online Encyclopedia for Genetic Epidemiology studies. http://www.oege.org/
39. A reappraisal of the kappa coefficient. W Thompson S Walter, J Clin Epidemiol 1988 41 10 949 958 10.1016/0895-4356(88)90031-5 3057117
40. The dependence of Cohen's kappa on the prevalence does not matter. W Vach, J Clin Epidemiol 2005 58 7 655 661 10.1016/j.jclinepi.2004.02.021 15939215
41. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. http://www.cypalleles.ki.se/
42. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. D Lewis E Watson B Lake, Mutat Res 1998 410 3 245 270 10.1016/S1383-5742(97)00040-9 9630657
43. Field-based evidence of fast and global increase of Plasmodium falciparum drug-resistance by DNA-microarrays and PCR/RFLP in Niger. M Ibrahim N Steenkeste N Khim H Adam L Konaté J Coppée F Ariey J Duchemin, Malar J 2009 8 32 10.1186/1475-2875-8-32 19236701
44. Consensus Human Arylamine N-Acetyltransferase Gene Nomenclature. http://louisville.edu/medschool/pharmacology/NAT.html